亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药-B

休市中 07-18 16:08:35

79.900

+3.100

+4.04%

最高80.700	最低75.600	成交量730.43万
今开76.850	昨收76.800	日振幅6.64%
总市值279.65亿	流通市值279.65亿	总股本3.50亿
成交额5.78亿	换手率2.09%	流通股本3.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":79.9,"timestamp":1752826115005,"preClose":76.8,"halted":0,"volume":7304319,"delay":0,"floatShares":350000000,"shares":350000000,"eps":-1.4659220350352942,"marketStatus":"休市中","change":3.1,"latestTime":"07-18 16:08:35","open":76.85,"high":80.7,"low":75.6,"amount":577622048,"amplitude":0.066406,"askPrice":80,"askSize":2500,"bidPrice":79.9,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-1.4659220350352942,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753061400000},"marketStatusCode":7,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":76.8,"openAndCloseTimeList":[[1752802200000,1752811200000],[1752814800000,1752825600000]],"volumeRatio":0.4882226900902386,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2552456415","title":"亚盛医药-B盘中异动 早盘急速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552456415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552456415?lang=zh_cn&edition=full","pubTime":"2025-07-18 11:10","pubTimestamp":1752808207,"startTime":"0","endTime":"0","summary":"2025年07月18日早盘11时10分，亚盛医药-B股票出现异动，股价急速上涨5.01%。截至发稿，该股报80.650港元/股，成交量428.705万股，换手率1.23%，振幅6.58%。亚盛医药-B股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，歌礼制药-B、加科思-B、中国抗体-B涨幅较大，振幅较大的相关个股有歌礼制药-B、三叶草生物-B、北海康成-B，振幅分别为15.03%、14.58%、13.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811100797aa9439&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811100797aa9439&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2552688105","title":"首个国产原研！亚盛医药创新抗癌药国内获批上市，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2552688105","media":"澎湃新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552688105?lang=zh_cn&edition=full","pubTime":"2025-07-17 14:02","pubTimestamp":1752732157,"startTime":"0","endTime":"0","summary":"Bcl-2抑制剂可特异性地结合并抑制Bcl-2蛋白，有效恢复肿瘤细胞的凋亡通路，诱导癌细胞死亡。此次中国原创、全球创新的药物有望改写全球Bcl-2抑制剂市场的竞争格局。利沙托克拉是亚盛医药第二个获批上市、进入商业化阶段的原创新药，未来是否也会考虑BD？亚盛医药目前已经有两款产品获批，“我们希望2027年做到收支平衡有利润”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071714035797a95af1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071714035797a95af1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK4139","AAPG"],"gpt_icon":0},{"id":"2552122596","title":"每日卖空追踪 | 亚盛医药-B 07月16日卖空量成交54.03万股，卖空比例为6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552122596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552122596?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:30","pubTimestamp":1752654641,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间07月16日，涨2.86%，卖空量成交54.03万股%，较上一交易日减少66.55%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172912a6ad2307&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172912a6ad2307&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2552594122","title":"亚盛医药-B07月16日获主力加仓1432.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552594122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552594122?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:15","pubTimestamp":1752653740,"startTime":"0","endTime":"0","summary":"07月16日, 亚盛医药-B股价涨2.86%，报收73.85元，成交金额6.6亿元，换手率2.57%，振幅5.29%，量比0.71。亚盛医药-B今日主力资金净流入1432.6万元，连续3日净流入，上一交易日主力净流入1.2亿元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为58.82%，平均涨幅为3.35%。该股近5个交易日下跌9.62%，主力资金累计净流入7719.7万元；近20日主力资金累计净流入2.5亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170416a6ad126a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170416a6ad126a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2551124121","title":"创新药概念走势向好 复宏汉霖涨9.72% 机构指板块估值仍具吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2551124121","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551124121?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:41","pubTimestamp":1752644466,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念走势向好，派格生物医药 涨10.83%，复宏汉霖涨9.72%，康方生物涨7.13%，亚盛医药涨4.25%，诺诚健华涨3.5%。对于创新药出海演变方向，该机构观察以下趋势：1）行业进一步衍生出了NewCo等新型交易模式；2）ADC赛道交易兴趣度最高，双抗/多抗、小核酸/mRNA等前沿技术领域亦存在较多机会。基于当前国产创新药资产储备丰富且交易性价比仍显着、MNC存在专利补缺需求、海外投融资边际改善，该机构认为2H25-2026年出海交易热度仍将延续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716135524a6acadc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716135524a6acadc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09926","02565","BK1574","09969","06855","06978","02696"],"gpt_icon":0},{"id":"2551111185","title":"港股异动 | 亚盛医药(06855)午前涨超4% 公司配股净筹近15亿港元 加速商业化及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2551111185","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551111185?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:54","pubTimestamp":1752638052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药午前涨超4%，截至发稿，涨4.11%，报74.75港元，成交额4.95亿港元。消息面上，亚盛医药近日宣布，拟按每股68.60港元的价格发行最多2200万股新股，配售事项所得净额约为14.93亿港元。董事认为，配售事项及认购事项将进一步巩固本集团的财务状况，并为本集团提供额外营运资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","AAPG","159992","BK1161","BK4139","06855","BK1574"],"gpt_icon":0},{"id":"2551816923","title":"每日卖空追踪 | 亚盛医药-B 07月15日卖空量成交109.17万股，卖空比例为2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551816923","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551816923?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:30","pubTimestamp":1752568234,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间07月15日，跌3.88%，卖空量成交109.17万股%，较上一交易日减少23.56%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715172752a44c026e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715172752a44c026e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2551132119","title":"越疆折价配股合共净筹约25亿港元 盘初股价均走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2551132119","media":"金吾资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551132119?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:48","pubTimestamp":1752544097,"startTime":"0","endTime":"0","summary":"金吾财讯 | 越疆 及亚盛医药均折价配股抽水，合共净筹约25亿港元，盘初股价均走低。截至发稿，越疆报58.3港元，跌2.83%，成交额5718.93万港元；亚盛医药报71.7港元，跌4.02%，成交额19.13亿港元。公司有90日禁售承诺。亚盛医药宣布，拟先旧后新配售最多2200万股新股份，占扩大后的已发行股本约5.92%，每股配售价为68.6港元，较上交易日收市价74.7港元折让约8.17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509485097a65f98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509485097a65f98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG","06855"],"gpt_icon":0},{"id":"2551325541","title":"亚盛医药-B盘中异动 早盘快速下挫5.42%报70.650港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551325541","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551325541?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:30","pubTimestamp":1752543007,"startTime":"0","endTime":"0","summary":"2025年07月15日早盘09时30分，亚盛医药-B股票出现波动，股价大幅跳水5.42%。截至发稿，该股报70.650港元/股，成交量2325.25万股，换手率6.66%，振幅0.80%。亚盛医药-B股票所在的生物技术行业中，整体涨幅为0.19%。该信息摘要如下：中金发布研报称，考虑到利生妥获批上市及全球适应症拓展前景，维持亚盛医药-B跑赢行业评级，根据DCF模型，上调目标价27.5%至88港币，较当前股价有15.3%的上行空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507150930089542c63c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507150930089542c63c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2551813173","title":"2025年医药行业发展动态与趋势洞察——资本运作与市场表现分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2551813173","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551813173?lang=zh_cn&edition=full","pubTime":"2025-07-15 08:20","pubTimestamp":1752538840,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，2025年的医药行业正经历深刻变革，政策推动、技术创新与资本市场活跃度持续提升。今日发布的亚盛医药-B配售及认购公告，再次印证了医药企业在融资策略上的前瞻性，为行业提供了新的观察视角。大额融资将进一步强化亚盛在医药研发领域的资源储备，尤其在肿瘤、抗病毒等核心赛道的管线推进中发挥关键作用。亚盛此次交易不仅补充了流动性，更巩固了其在创新药领域的竞争力，为后续临床试验及商业化落地提供坚实后盾。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071508363697a64acb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071508363697a64acb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2551332139","title":"亚盛医药-B拟先旧后新配售最多2200万股销售股份 净筹14.93亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551332139","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551332139?lang=zh_cn&edition=full","pubTime":"2025-07-15 06:30","pubTimestamp":1752532200,"startTime":"0","endTime":"0","summary":"预期认购事项将筹集的所得款项总额将约为15.09亿港元及估计认购事项产生的所得款项净额将约为 14.93亿港元。按此基准，每股销售股份的净价将约为67.84港元。董事认为，配售事项及认购事项将进一步巩固本集团的财务状况，并为本集团提供额外营运资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715063216a6a986a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715063216a6a986a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2551188991","title":"亚盛医药拟配股筹资最多15.4亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551188991","media":"DoNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551188991?lang=zh_cn&edition=full","pubTime":"2025-07-14 19:13","pubTimestamp":1752491583,"startTime":"0","endTime":"0","summary":"2025年7月14日，交易文件显示，亚盛医药计划通过先旧后新方式配售股份，预计筹资至多15.4亿港元（约1.96亿美元）。公司拟配售2,200万股股份，每股配售价在68.35至70港元之间，较上周一收盘价74.70港元折让6.3%-8.5%。此次配股旨在增强公司资金流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714191420954206e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714191420954206e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","06855","BK4139","AAPG"],"gpt_icon":0},{"id":"2551000559","title":"每日卖空追踪 | 亚盛医药-B 07月14日卖空量成交36.1万股，卖空比例为6.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551000559","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551000559?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:30","pubTimestamp":1752481833,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间07月14日，跌2.16%，卖空量成交36.1万股%，较上一交易日减少43.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172827a6a8690d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172827a6a8690d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2551920501","title":"中金：升亚盛医药-B(06855)目标价至88港元 评级“跑赢行业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551920501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551920501?lang=zh_cn&edition=full","pubTime":"2025-07-14 10:04","pubTimestamp":1752458674,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到利生妥获批上市及全球适应症拓展前景，维持亚盛医药-B跑赢行业评级，根据DCF模型，上调目标价27.5%至88港币，较当前股价有15.3%的上行空间。根据公司公告，此前，中国尚未有Bcl-2抑制剂获批用于治疗CLL/SLL，全球也仅艾伯维的维奈克拉获批上市。该行认为利生妥的获批上市有望为国内CLL/SLL后线患者带来新的治疗选择，建议关注后续商业化为公司业绩带来的增量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"2551927949","title":"亚盛医药利刃出鞘","url":"https://stock-news.laohu8.com/highlight/detail?id=2551927949","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551927949?lang=zh_cn&edition=full","pubTime":"2025-07-14 09:43","pubTimestamp":1752457417,"startTime":"0","endTime":"0","summary":"近日，根据NMPA官网的消息，亚盛医药万众期待的管线利沙托克拉片已附条件批准上市，用于既往经过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。利刃出鞘维奈克拉上市之后，近十年之久无后来者，而直到如今，第二款药物——利沙托克拉片才获批上市。亚盛医药的后备军作为一家目前市值已经较高的biotech，亚盛医药肯定不止奥雷巴替尼和APG-2575两个大单品支撑，后面肯定还有生力军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094538a6a78424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094538a6a78424&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","BK1574","06855","BK1161","AAPG"],"gpt_icon":0},{"id":"2550586749","title":"国产首个！亚盛医药 Bcl-2 抑制剂国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2550586749","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550586749?lang=zh_cn&edition=full","pubTime":"2025-07-11 19:28","pubTimestamp":1752233331,"startTime":"0","endTime":"0","summary":"这是首个在国内获批上市的国产原研Bcl-2抑制剂，同时也是近10年时间以来，全球第二个上市的Bcl-2抑制剂。在此次APG-2575获批上市之前，全球唯一获批上市的Bcl-2抑制剂，是两大跨国药企巨头艾伯维与罗氏联合开发的维奈克拉。根据弗若斯特沙利文的数据，细胞凋亡靶点小分子药物全球市场预计于2030年增长到360亿美元，其中Bcl-2抑制剂全球市场规模预计将达到217亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711193954a6a3c4ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711193954a6a3c4ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2550939037","title":"每日卖空追踪 | 亚盛医药-B 07月11日卖空量成交50.39万股，卖空比例为5.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550939037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550939037?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:30","pubTimestamp":1752222636,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间07月11日，跌5.1%，卖空量成交50.39万股%，较上一交易日增加33.94%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711172807a6a37f99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711172807a6a37f99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2550987149","title":"一周医药速览（07.07-07.11）","url":"https://stock-news.laohu8.com/highlight/detail?id=2550987149","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550987149?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:27","pubTimestamp":1752222452,"startTime":"0","endTime":"0","summary":"目前，市场上可用于小儿便秘的同类产品主要用于其他疾病伴发的便秘症状，临床尚无治疗小儿便秘的儿童专用中药创新药。甘李药业：预计上半年净利润增加100.73%到114.12%，胰岛素量价齐升甘李药业发布2025年半年度业绩预增公告。披露经财务部门初步测算，预计 2025 年半年度实现归属净利润为6亿元到6.4亿元，与上年同期相比，同比增加 100.73%到 114.12%。临床前多种动物模型研究结果显示，UBT37034与GLP-1类似物联用能显著降低体重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711162815a44457d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711162815a44457d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600566","01801","06855","BK4139","SVA","603087","03933"],"gpt_icon":0},{"id":"2550610718","title":"亚盛医药-B07月10日主力净流出2843.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2550610718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550610718?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:16","pubTimestamp":1752135362,"startTime":"0","endTime":"0","summary":"07月10日, 亚盛医药-B股价跌2.07%，报收80.45元，成交金额3.5亿元，换手率1.26%，振幅6.15%，量比1.02。亚盛医药-B今日主力资金净流出2843.2万元，上一交易日主力净流入1698.4万元。该股近5个交易日下跌3.25%，主力资金累计净流入1470.8万元；近20日主力资金累计净流入1.5亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170412a6a13df1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170412a6a13df1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2550314611","title":"国产首个！亚盛医药Bcl-2抑制剂“利沙托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2550314611","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550314611?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:43","pubTimestamp":1752133404,"startTime":"0","endTime":"0","summary":"APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。Bcl-2抑制剂的出现让CLL/SLL的治疗有了进一步的革新。不过Bcl-2靶点成药性难度很高，靶点发现至今近40年，全球只有一款靶向Bcl-2的抑制剂获批上市，即艾伯维维奈克拉，此外，百济神州的索托克拉已申请上市，目前正在审评当中。力胜克拉的获批将为患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710155605a44207f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710155605a44207f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","AAPG","BK1574","ASPHF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.0465},{"period":"1month","weight":0.1374},{"period":"3month","weight":1.1507},{"period":"6month","weight":1.0177},{"period":"1year","weight":1.7131},{"period":"ytd","weight":0.758}],"compareEarnings":[{"period":"1week","weight":0.0284},{"period":"1month","weight":0.047},{"period":"3month","weight":0.1603},{"period":"6month","weight":0.2676},{"period":"1year","weight":0.3964},{"period":"ytd","weight":0.2376}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤治疗药物的发现、研发及商业化的控股公司。该公司主营业务是从事开发及销售针对肿瘤、乙肝及衰老相关的疾病的新型小规模疗法。该公司的主要产品包括Olverembatinib（HQP1351）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918等产品。该公司的产品主要用于治疗主要血液系统恶性肿瘤，包括慢性粒细胞白血病、急性粒细胞白血病、慢性淋巴细胞白血病、急性淋巴细胞白血病、骨髓增生异常综合征及多发性骨髓瘤。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.093585},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.035469},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.10554},{"month":4,"riseRate":0.833333,"avgChangeRate":0.119495},{"month":5,"riseRate":0.5,"avgChangeRate":0.054537},{"month":6,"riseRate":0.833333,"avgChangeRate":0.306068},{"month":7,"riseRate":0.5,"avgChangeRate":-0.059814},{"month":8,"riseRate":0.8,"avgChangeRate":0.030238},{"month":9,"riseRate":0.2,"avgChangeRate":-0.085141},{"month":10,"riseRate":0.6,"avgChangeRate":0.075164},{"month":11,"riseRate":0.5,"avgChangeRate":0.0779},{"month":12,"riseRate":0.666667,"avgChangeRate":0.084992}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}